share_log

Earnings Call Summary | Journey Medical(DERM.US) Q1 2024 Earnings Conference

Futu News ·  May 14 16:56  · Conference Call

The following is a summary of the Journey Medical Corporation (DERM) Q1 2024 Earnings Call Transcript:

Financial Performance:

  • Journey Medical reported Q1 revenue of $13 million, a 7% increase year-over-year, with Qbrexza and Accutane contributing over $10.8 million. The company realized significant reduction in SG&A expenses and achieved profitability in Q1. Over 90% of the company's revenue comes from Qbrexza, Accutane, Amzeeq, and Zilxi. The company's cash resources reached $24.1 million at the end of Q1 2024.

Business Progress:

  • Qbrexza and Accutane gained market share, expected to drive growth throughout 2024. Journey Medical is preparing to launch DFD-29 for Rosacea treatment following positive Phase 3 trial results. The FDA has accepted the new drug application for DFD-29, with a planned date in November. The company is exploring opportunities to out-license its IP and acquire or in-license FDA-approved products. The company expects net revenues in the range of $55 to $60 million by the year-end.

More details: Journey Medical IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment